Roles
- Professor of Clinical Pediatrics
- Director, Hemophilia and Thrombosis Comprehensive Treatment Center
- Medical Director, Pediatric Hemophilia Program
- Director, Pediatric Hematology-Oncology Fellowship Program
-
Biography
Dr. Fernando Corrales-Medina is a Professor of Clinical Pediatrics at the University of Miami-Miller School of Medicine, Division of Pediatric Hematology-Oncology, where he serves as the director of the University’s Comprehensive Hemophilia and Thrombosis Treatment Center, medical director for the pediatric hemophilia program and director for the pediatric hematology-oncology fellowship program.
After attending medical school in Peru, he completed his general pediatrics training at Jackson Memorial/University of Miami in 2011, followed by his pediatric hematology-oncology fellowship at The University of Texas – MD Anderson Cancer Center, from which he graduated in 2014.
Dr. Corrales-Medina’s primary academic interests are von Willebrand disease (VWD),hemophilia A, women with bleeding disorders, novel hemostatic therapies, and the use of point-of-care musculoskeletal ultrasound in bleeding disorders. He is the Principal Investigator for several pharmaceutical, as well as investigator-initiated, research studies. His work has been published in several peer-reviewed journals, including Blood Reviews, Haemophilia, Journal of Thrombosis and Haemostasis, Research and Practice in Hemostasis and Thrombosis, among others.
Dr. Corrales-Medina has received several research and teaching awards including the 2018 American Thrombosis and Hemostasis Network (ATHN) - DREAM Award. Currently, he is the director of the University of Miami-VWD Academy for Latin America and the principal investigator for the global initiative “VWDtest.com” and the ATHN Transcends-Hemophilia Natural History Arm Study. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
Dr. Fernando F. Corrales-Medina’s teaching interests center on pediatric hematology, with particular expertise in hemostasis and thrombosis, including hemophilia, von Willebrand disease, rare bleeding disorders, pediatric thrombosis, and anticoagulation. His educational approach emphasizes the integration of pathophysiology, clinical reasoning, and evidence-based medicine, with the goal of helping learners translate increasingly complex diagnostic and therapeutic advances into thoughtful, individualized patient care.
As Director of the Pediatric Hematology-Oncology Fellowship Program at the University of Miami, Dr. Corrales-Medina is actively involved in graduate medical education and the training and mentorship of fellows, residents, medical students, and other healthcare professionals. He has a particular interest in developing clinical reasoning and progressive independence among trainees, while emphasizing critical appraisal of the medical literature, multidisciplinary collaboration, effective communication, and patient-centered decision-making.
An important component of his teaching focuses on hemostasis and thrombosis education. He teaches learners to approach bleeding and thrombotic disorders systematically, integrating the clinical phenotype with laboratory findings and recognizing the limitations of diagnostic testing. His educational interests also include the rapidly evolving therapeutic landscape in hemophilia and other bleeding disorders, appropriate use of anticoagulant therapies, and the incorporation of point-of-care musculoskeletal ultrasound into the comprehensive assessment of patients with hemophilia.
Beyond institutional education, Dr. Corrales-Medina is committed to expanding education in bleeding disorders through national and international programs. He has developed and participated in educational initiatives for physicians and multidisciplinary healthcare professionals, with a particular emphasis on Latin America and the Caribbean. Through these efforts, he seeks to promote evidence-based, practical approaches that can be adapted to different healthcare environments and levels of available resources.
Across his educational activities, Dr. Corrales-Medina views mentorship as an essential component of academic medicine. His teaching aims not only to develop clinical expertise, but also to foster intellectual curiosity, scholarly inquiry, leadership, and the skills necessary for trainees to become independent clinicians, educators, and investigators. -
Research Interests
Dr. Fernando F. Corrales-Medina’s research focuses on improving the diagnosis, treatment, and long-term outcomes of children and adults with inherited bleeding and thrombotic disorders. His work is centered on translating advances in hemostasis and thrombosis into clinically meaningful improvements in patient care, with particular emphasis on von Willebrand disease (VWD), hemophilia, rare bleeding disorders, and pediatric thrombosis.
A major area of his research is the recognition and diagnosis of VWD and other inherited bleeding disorders, particularly in children, adolescents, and women with heavy menstrual bleeding. His work has examined the clinical utility and limitations of conventional laboratory testing, bleeding assessment tools, and specialized von Willebrand factor assays, with the goal of identifying patients who may otherwise remain undiagnosed. He is also involved in initiatives using digital tools to improve recognition of abnormal bleeding and facilitate access to appropriate evaluation.
In hemophilia, Dr. Corrales-Medina’s research interests include contemporary prophylaxis, non-factor therapies, treatment individualization, joint health, and the evolving definition of optimal hemostatic protection. His work incorporates clinical outcomes and point-of-care musculoskeletal ultrasound to better characterize joint health and support individualized treatment decisions. He also participates in multicenter observational research evaluating the natural history and real-world treatment of people with hemophilia and other inherited bleeding disorders.
His research in thrombosis focuses on pediatric and young-adult venous thromboembolism, thrombophilia, anticoagulant therapy, and anticoagulation stewardship, including populations with complex chronic disease and elevated thrombotic risk. Across these areas, he is particularly interested in determining how laboratory findings and emerging diagnostic technologies should be translated into decisions that meaningfully alter clinical management.
An additional focus of his academic work is reducing disparities in the recognition and management of bleeding disorders through education, international collaboration, and capacity building, particularly in Latin America and other resource-limited settings. Ultimately, his research seeks to bridge diagnostic science, therapeutic innovation, and real-world clinical practice to deliver more precise, accessible, and patient-centered care for individuals with bleeding and thrombotic disorders. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Von Willebrand Academy for Latin America Returns to the Miller School
Dr. Charles Mitchell Honored by The Batchelor Foundation
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 8 clinical trials.
-
Jivi interventional study to assess a new risk score approach.This study aims to assess a new risk score approach utilizing the best known phenotypic and biologic variables to select the most appropriate prophylaxis regimen for reaching a favorable outcome when switching from standard half-life (SHL) human coagulation factor VIII (FVIII) treatment to Jivi.
- Principal Investigator: Fernando Corrales Medina
- Study Phase: N/A
- Enrollment Status: Closed
-
A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and <70 Years With Severe or Moderate Hemophilia A Without FVIII Inhibitors on Emicizumab Prophylaxis
- Principal Investigator: Fernando Corrales Medina
- Study Phase: Phase 4
- Enrollment Status: Not Accepting
-
To evaluate the efficacy of NXT007 prophylaxis compared with emicizumab prophylaxis based on the non-inferiority assessment of treated bleeds
- Principal Investigator: Fernando Corrales Medina
- Study Phase: TBD
- Enrollment Status: Open
-
Objectives and endpointsPrimary objective:• To investigate long-term safety of Mim8 prophylaxis in participants with haemophilia A with or without FVIII inhibitorsPrimary endpoint:• Number of treatment-emergent adverse events (TEAEs)
- Principal Investigator: Fernando Corrales Medina
- Study Phase: TBD
- Enrollment Status: Open
-
Emicizumab is a humanized, monoclonal bispecific antibody developed to bind activated FIX and FX on the phospholipid membrane and mimic FVIII cofactor functionality.[9, 10] Emicizumab administration is via subcutaneous injection, has a half-life of 4-5 weeks, and is approved for prophylaxis in individuals with hemophilia A with and without inhibitors.[10-13] Real-world experience with emicizumab in persons with hemophilia A with or without inhibitors is growing, has demonstrated effective bleed control, and has demonstrated safety with no thrombosis/thrombotic microangiopathy or deaths in a recent, large single-center study.[14] Additional safety analysis of HAVEN 1, 2, and 4 trials has demonstrated no thrombotic microangiopathy or thromboembolic events, in those patients also treated with recombinant factor VIIa (rFVIIa).[15]Though its use in the hemophilia A population is growing, additional potential emicizumab applications for hemostatic control in other hemostatic disorders remain unknown. A recent case report highlighted the hemostatic efficacy of emicizumab off- label use in type 3 von Willebrand Disease (VWD), another severe bleeding disorder.[16] This pediatric patient had type 3 VWD with alloantibodies and a bleeding phenotype similar to hemophilia A with inhibitor patients, requiring suboptimal bleeding management with rFVIIa and activated prothrombin complex concentrates (aPCC).[16] Emicizumab prophylaxis was initiated and the patient no longer required aPCC prophylaxis and rare use of rFVIIa for acute bleeding events (only 1 trauma-induced soft tissue hematoma at the time of publication).[16] The authors concluded their report suggested the bleeding phenotype in type 3 VWD is expressed mainly due to factor VIII deficiency.[16] This study suggests a potential additional application for emicizumab insevere VWD.Benefits and Risk Assessment[Hemlibra,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf] Benefit conferred through emicizumab prophylaxis may be considerable as similar challenges for prophylaxis in VWD may exist as those with hemophilia prophylaxis, including patient adherence, venous access, and cost among others.[17] Prophylaxis in VWD is a relatively recent recommendation, with first formal endorsement in the 2021 VWD management guidelines as result of analysis of limited available data.[3, 18-20] Individuals with VWD have varied bleeding phenotypes, and those requiring prophylaxis may be related to recurrent epistaxis, excessive menstrual bleeding, musculoskeletal bleeding, or other frequent bleeding symptoms.[3] Emicizumab prophylaxis may be beneficial in severe VWD and VWD/hemophilia A by providing consistent, baseline thrombin generation and alleviate recurrent bleeding as suggested in the literature thusfar.[16]Risk for emicizumab prophylaxis in severe VWD and VWD/hemophilia A would be hypothesized to be similar to those safety data recently reported from the combined experience in persons with hemophilia A in the HAVEN trials.[15[Hemlibra, , https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf]]Emicizumab treatment benefit will be determined through evaluation of a 12-month pretreatment bleeding history (through retrospective chart review prior to study enrollment) and describing bleeding history for 12-months of emicizumab prophylaxis therapy. Treatment success will be defined as reduction in annualized bleed rate (ABR), including musculoskeletal bleeding (similar to that of hemophilia A) and mucocutaneous bleeding, and will be evaluated through descriptive statistical analysis. Risk mitigation measures will be in place including strict eligibility criteria of severe VWD or VWD and hemophilia A (as outlined in inclusion criteria) with bleeding phenotypes suggestive ofprophylaxis treatment benefit [3], as well as safety and toxicity monitoring via a datamonitoring committee (DMC). Any breakthrough bleeding events would be allowed treatment via standard antifibrinolytic, desmopressin (DDAVP), or VWF concentrate at the discretion of the treating provider.This trial will enroll patients with severe VWD with a significant bleeding phenotype warranting prophylaxis per discretion of the treating provider and concomitant VWD/Hemophilia A. Given the limited treatment options for these patients, this population is considered appropriate for trials of novel therapeutic candidates. Thebenefit-risk ratio for emicizumab is expected to be acceptable in this setting.
- Principal Investigator: Fernando Corrales Medina
- Study Phase: TBD
- Enrollment Status: Open
-
To evaluate the prevalence of hemophilic joint changes (including but not limited to synovial changes, joint effusion, synovitis, cartilage damage and subchondral bone damage) in hemophilia female carriers, using a previously validated ultrasound scoring system and protocol
- Principal Investigator: Fernando Corrales Medina
- Study Phase: N/A
- Enrollment Status: Closed
-
In the study the research team has the objective of looking at the use of a neck ultrasound to determine the risk for high blood pressure in pediatric patients with hemophilia, as we believe that they might be at higher risk for high blood pressure due to medications they currently receive as standard of care.
- Principal Investigator: Fernando Corrales Medina
- Study Phase: N/A
- Enrollment Status: Closed
-
Amultinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8)in adults and adolescents with haemophilia A with or without FVIIIinhibitors.
- Principal Investigator: Fernando Corrales Medina
- Study Phase: Phase III
- Enrollment Status: Closed